Introduction {#S1}
============

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumor of the skin with high rates of recurrence, metastasis, and mortality. The incidence of MCC has nearly tripled in the past 20 years and this malignancy is more prevalent in the immunosuppressed and elderly. The 5-year overall survival from time of diagnosis is 30-64%. Survival decreases upon metastasis to lymph nodes, distant skin sites, or distant organs ([@R9]).

There is increased risk for MCC in solid organ transplant recipients, chronic lymphocytic leukemia patients, and HIV-infected patients, suggesting an infectious etiology for this malignancy ([@R8]; [@R17]; [@R35]; [@R46]). The DNA of a novel virus, Merkel cell polyomavirus (MCPyV), has been identified in approximately 80% of MCCs ([@R3]; [@R8]; [@R11]; [@R19]; [@R21]; [@R22]; [@R32]; [@R33]). MCPyV may contribute to tumorigenesis via a truncated large T antigen (LTAg) and small T antigen (STAg), which inhibit the tumor suppressor retinoblastoma (RB) and promote signaling by the mammalian target of rapamycin pathway, respectively ([@R28]; [@R52]; [@R53]). Mechanisms of tumorigenesis specific to MCPyV-negative tumors are less well understood, although altered expression of RB, p53, and/or c-KIT suggest that these molecules may play a role ([@R7]; [@R55]; [@R61]).

To our knowledge, transcriptional profiles of MCPyV-negative and -positive tumors have not been compared. To nominate candidate genes involved in MCPyV-independent MCC tumorigenesis, we performed DNA microarray analysis of Merkel cell carcinoma tumors and correlated profiling results with MCPyV tumor status.

Results {#S2}
=======

Patient demographics {#S3}
--------------------

Patient demographic information is summarized in [Table 1](#T1){ref-type="table"}. The study included 30 tumors from 27 patients (14 men and 13 women) diagnosed with MCC between 2005 and 2010. The mean patient age at diagnosis was 75 years. Two patients were immunosuppressed at the time of diagnosis due to organ transplant. Two additional patients had chronic lymphocytic leukemia.

Transcriptional profiling demonstrates distinct gene expression patterns in Merkel cell carcinoma compared with other primary cutaneous carcinomas {#S4}
--------------------------------------------------------------------------------------------------------------------------------------------------

To characterize gene expression patterns in MCC, we analyzed transcriptional profiles of 19 primary MCCs, 11 metastatic MCCs, three MCC cell lines, four primary cutaneous squamous cell carcinomas (SCCs), and two basal cell carcinomas (BCCs). Oligonucleotide arrays with over 54,000 probe-sets representing over 47,400 transcripts were utilized. To generate an unsupervised two-dimensional representation of relative gene expression across all tumors, we performed principal component analysis (PCA) of all probe-sets. The resulting PCA plot demonstrated clear distinction of MCCs from SCCs and BCCs, with only one outlier ([Figure 1](#F1){ref-type="fig"}). Cultured MCC cells, which represent a pure population of tumor cells, assorted with MCC tumor specimens. The single MCC outlier case was morphologically similar to other MCC tumors in the cohort, but had lower tumor volume than other samples.

For all analyses, significant differential expression was defined as at least 2-fold differential expression in either direction, with an adjusted p-value of ≤ 0.05. Relative to squamous cell carcinomas, MCCs demonstrated significant differential expression of over 4000 probe-sets ([Figure S1, Table S1](#SD1){ref-type="supplementary-material"}, and data not shown), with a false discovery rate of 1.8%. In validation of our approach, our screen identified established diagnostic markers of MCC including cytokeratin 20, chromogranin A, synaptophysin, and NCAM1, as well as known markers for SCC such as cytokeratin 5/6 and TP63 ([Table S1](#SD1){ref-type="supplementary-material"}). In addition, we observed upregulation of the proposed mechanoreceptor genes Piezo2 (*FAM38B*) and *TRPC1* ([@R14]; [@R15]; [@R23]). To screen for upregulated genes with potential roles in tumorigenesis, we searched the data set for the term "oncogene" in the gene description, and filtered these candidates by literature search to identify genes with known roles in cancer biology. Using this method, we identified potentially protumorigenic genes including *FYN, AKT3, MYB, RAB3B, JUND,* and *FEV* ([Table S1](#SD1){ref-type="supplementary-material"})([@R27]; [@R41]; [@R47]; [@R50]; [@R51]; [@R57]). In further validation of our data set, we also found upregulation of genes previously reported to be expressed in MCC, including *SOX2*, *BCL2*, *MYCL1*, *VEGFA*, *GPC3*, *ATOH1*, *HIP1*, and *KIT* ([Table S1](#SD1){ref-type="supplementary-material"})([@R1]; [@R4]; [@R12]; [@R20]; [@R26]; [@R34]; [@R36]; [@R38]; [@R40]; [@R45]; [@R49]; [@R56]). We also identified upregulation of numerous genes previously described as expressed in benign Merkel cells, including neuronal transcription factors, presynaptic molecules, and ion channels ([Table S1](#SD1){ref-type="supplementary-material"})([@R25]).

The group of over- or under-expressed genes in MCC relative to SCC was assessed for functional clusters by gene ontology (GO) analysis, which revealed that MCCs were enriched for gene sets associated with neural differentiation ([Table S2](#SD1){ref-type="supplementary-material"}). Comparison with a database of gene expression profiles via parametric gene set analysis revealed similarity between MCC and tumors including neuroblastoma ([Figure S2](#SD1){ref-type="supplementary-material"}).

Comparison of MCC with BCC yielded 650 significantly different probe-sets. Genes upregulated in BCC relative to MCC included the Hedgehog pathway transcripts *GLI1*, *GLI2*, *PTCH1*, and *PTCH2*, as well as the Hedgehog target basonuclin ([Table S3](#SD1){ref-type="supplementary-material"}), consistent with the known role of Hedgehog signaling in BCC ([@R16]; [@R31]).

In silico comparison of MCC with normal skin demonstrated significant difference in expression in \> 8000 probe-sets, with significant differential expression defined as at least 2-fold differential expression in either direction, with an adjusted p-value of ≤ 0.05. PCA demonstrated clear separation between groups ([Figure S3](#SD1){ref-type="supplementary-material"}). We observed differential expression of MCC diagnostic markers, proposed mechanoreceptor genes, and protumorigenic genes ([Table S4](#SD1){ref-type="supplementary-material"}).

MCPyV status and clinical features {#S5}
----------------------------------

By PCR detection of MCPyV DNA and RNA, we found that 12/26 (46%) of tumors in our cohort were MCPyV-positive and 14/26 (54%) were MCPyV-negative ([Figure S4](#SD1){ref-type="supplementary-material"}). There was no significant difference in age at diagnosis and stage at presentation between MCPyV-negative and MCPyV-positive groups. Tumors showed significantly different anatomic distribution by MCPyV status (p = 0.029). Specifically, eight of eleven (73%) MCPyV-negative primary tumors were located in the head and neck region and three (27%) were on the upper extremities, whereas none were on the lower extremity. In contrast, three of twelve (25%) MCPyV-positive primary tumors were located on the head and neck, four (33%) on the upper extremity, and five (42%) on the lower extremity.

Transcriptional profiling identifies distinct gene expression patterns in MCPyV-negative MCC {#S6}
--------------------------------------------------------------------------------------------

We analyzed gene expression patterns in MCPyV-positive versus -negative tumors. By PCA of all probe-sets, the majority of MCPyV-positive tumors formed a cluster which displayed partial overlap with MCPyV-negative tumors ([Figure 2](#F2){ref-type="fig"}). 1593 probe-sets displayed significant differential expression between MCPyV-positive and -negative tumors, with a false discovery rate of 1.9% ([Figure 3](#F3){ref-type="fig"} and data not shown). By GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, MCPyV-negative tumors displayed relative upregulation of gene groups associated with Notch signaling and receptor tyrosine kinase signaling, among others ([Table 2](#T2){ref-type="table"} and data not shown).

Merkel cell polyomavirus-positive tumors are enriched for peritumoral lymphoctyes {#S7}
---------------------------------------------------------------------------------

GO and KEGG analyses identified enrichment for a number of gene groups associated with immune response in the MCPyV-positive tumor cohort including *CD3G, CD3D, ZAP70* and *IGHM*, suggesting increased presence of tumoral lymphocytes. Thus, we performed immunohistochemical studies to define the immune infiltrate associated with MCPyV-positive tumors. Relative to MCPyV-negative tumors, MCPyV-positive tumors were associated with significantly increased CD8+ cells (fold 14.0, p = 0.01) ([Figure 4](#F4){ref-type="fig"}). There was also a trend toward increased CD3+ cells (fold 3.1, p = 0.10). CD4+ T-cells were scant in both MCPyV-positive and -negative tumors. CD20+ B-cells were variable, with no significant difference between groups (data not shown).

In our cohort, most lymphocytes were in the peritumoral stroma or associated with tumoral vessels, with only a small number of tumor-infiltrating lymphocytes (TILs). We observed a trend toward slightly increased CD8+ TILs in MCPyV-positive tumors, which did not reach statistical significance (fold 2.4, p = 0.06).

Retinoblastoma expression is decreased in MCPyV-negative MCC {#S8}
------------------------------------------------------------

Previous reports have described increased RB protein expression in MCPyV-positive tumors ([@R7]; [@R55]), although other reports found no association ([@R29]; Schrama *et al.*, 2011). We observed a 2.4-fold upregulation of *RB1* in MCPyV-positive tumors by microarray ([Table 2](#T2){ref-type="table"}). By immunohistochemistry analysis, 7/7 (100%) of MCPyV-positive tumors were diffusely positive (\>50% of cells) for expression of RB protein ([Figure 4](#F4){ref-type="fig"}). In contrast, only 1/14 (7%) of MCPyV-negative tumors showed diffuse RB expression, 5 (36%) cases displayed intermediate levels of expression (10-50% of cells), and 8 (57%) lacked significant expression.

Discussion {#S9}
==========

Transcriptome profiling by DNA microarray analysis is a powerful tool for identifying gene expression changes within tumors and tumor subgroups. Here, we report gene expression profiles of 30 MCCs, with direct comparison to 4 primary cutaneous SCCs and 2 BCCs, as well as *in silico* comparison to 64 normal skin samples. In support of the biological validity of our expression profiles, our screen identified upregulation of diagnostic markers for MCC, including CK20 and neuroendocrine markers, with respect to normal skin and SCC. We also identified increased expression of genes which may play protumorigenic roles in MCC, including *FYN* and *FEV*. Further expression and functional studies are needed to characterize the roles of these genes in MCC.

Uncertainty regarding the cell of origin for MCC contributes to difficulty in understanding mechanisms of MCC tumorigenesis. Historically, MCC was thought to arise from Merkel cells, which are mechanoreceptor cells in the basal epidermis that share immunohistochemical and ultrastructural features with MCC. However, this theory has been debated because MCC often spares the epidermis, whereas benign Merkel cells are intraepidermal ([@R48]; [@R60]). MCCs in our cohort displayed differential regulation of genes with proposed roles in mechanosensation and/or known expression in benign Merkel cells ([@R14]; [@R15]; [@R23]; [@R25]). In addition, functional gene set analysis identified that MCC was enriched for gene clusters expressed in the inner ear, an organ with known developmental similarities to benign Merkel cells. These findings further demonstrate the similarity between MCC and benign Merkel cells.

The discovery and characterization of MCPyV has provided a mechanism by which benign Merkel cells or progenitor stem cells may undergo malignant transformation ([@R2]). Mechanisms of tumorigenesis in MCPyV-negative MCC are less clear. Evidence suggests that tumors with low/absent viral DNA and/or lack of LTAg expression are associated with loss of RB expression ([@R6], [@R7]; [@R55]), increased c-KIT expression ([@R61]), increased p53 expression ([@R7]; [@R61]), and *TP53* mutations in a subset ([@R55]). Although previous studies have performed gene expression microarray analysis of benign mouse Merkel cells, MCC cell lines, and MCC tumors ([@R25]; [@R44]; Van Gele *et al.*, 2004), these studies did not compare gene expression profiles of MCPyV-positive and MCPyV-negative tumors.

In MCPyV-positive MCC, viral LTAg has been shown to promote tumor growth by binding and inactivating the tumor suppressor protein RB ([@R28]; [@R52]). The role of RB in MCPyV-negative MCC pathogenesis has been unclear, with some studies demonstrating decreased RB expression ([@R6]; [@R55]), while others finding no difference ([@R29]). Our study demonstrated 2.4-fold lower *RB1* expression in MCPyV-negative tumors relative to MCPyV-positive tumors by gene expression microarray. Perhaps more significantly, the majority of MCPyV-negative MCC displayed absence of RB protein expression, whereas RB was diffusely expressed in all MCPyV-positive tumors. Thus, loss of RB activity may be integral to MCC pathogenesis, either through its inactivation by LTAg in MCPyV-positive tumors, or by loss of RB expression in MCPyV-negative tumors. Deletions at the RB locus have been described in MCC ([@R37]; [@R39]; [@R45]; [@R59]). A subset of MCPyV-negative tumors retained RB expression, suggesting that an alternative mechanism of RB pathway dysregulation may occur in these tumors.

The relationship of MCPyV status with various clinical parameters is under active investigation. Age and stage at presentation were not significantly related to MCPyV status in our study. In agreement with previous reports ([@R42]; [@R55]), we observed a significantly higher incidence of MCPyV-negative MCC tumors on the head and neck, whereas more MCPyV-positive MCC tumors were located on limbs. The incidence of MCPyV by PCR in our cohort was lower (46%) than the commonly reported 70-80% ([@R8]). Because the influence of factors such as immune status and geography on MCPyV incidence in MCC is incompletely understood, we cannot rule out the possibility that clinical/epidemiologic factors are affecting the rate of MCPyV positivity in our cohort.

Several lines of evidence suggest that both cellular and humoral responses occur in response to viral antigens expressed in MCPyV-positive MCC. Serum antibodies against MCPyV TAg are relatively specific for the presence of active MCC, whereas antibodies against viral capsid proteins are less specific ([@R13]; [@R18]; [@R43]; [@R45]; [@R58]). MCPyV-reactive CD4+ and CD8+ T cells have been isolated from MCPyV-positive MCC tumors, but are absent from MCPyV-negative tumors ([@R30]). Furthermore, one study found that MCPyV-positive tumors are associated with significantly increased CD3+ and CD8+ TILs as well as tumor-infiltrating monocytes, although another study did not corroborate these findings with respect to CD8+ T-cells ([@R44]; [@R54]). By gene ontology analysis, we observed increased expression of immune response genes in MCPyV-positive tumors, consistent with the presence of increased tumoral lymphocytes.

Immunohistochemistry revealed significantly increased CD8+ T cells in the peritumoral stroma of MCPyV-positive tumors. Together with previous studies, our results indicate that MCPyV-associated cellular immune response appears to consist predominantly of CD8+ lymphocytes ([@R30]; [@R54]), although we observed the immune response to consist of predominantly peritumoral lymphocytes rather than TILs.

In summary, we report a transcriptome-wide comparison of MCPyV-positive MCC with MCPyV-negative MCC. RB expression is lost in the majority of MCPyV-negative tumors, supporting the concept that RB deregulation is a key alteration in MCC. Our data are in keeping with the notion of two distinct classes of MCC based on viral status. Further studies evaluating the Notch pathway and receptor tyrosine kinases are underway to elucidate their role in the pathogenesis of MCC.

Materials and methods {#S10}
=====================

Tumor procurement and cell lines {#S11}
--------------------------------

Studies were approved by the Institutional Review Board of the University of Michigan. For all tumors, MCC diagnosis was confirmed by morphology and immunohistochemistry at the time of diagnosis. All tumor tissue was procured from the University of Michigan Hospitals Cutaneous Surgery and Oncology Program. At time of collection, tumor tissue was flash-frozen in liquid nitrogen and stored at -80°C until RNA extraction. Formalin-fixed paraffin-embedded tissue for tissue microarray construction was obtained from archival tissue blocks. The adequacy of frozen section and paraffin-embedded tissue was confirmed by two pathologists (DF and PH).

RNA was prepared from normal skin and processed for microarray analysis as previously described ([@R24]).

Merkel cell carcinoma cell lines were established at the University of Michigan from tumor tissue procured as described above, with additional details on cell line establishment in [Supplemental Materials and Methods](#SD1){ref-type="supplementary-material"}.

RNA isolation {#S12}
-------------

Areas with at least 70% tumor cellularity were targeted for RNA isolation, using hematoxylin and eosin stains obtained on frozen sections for each specimen. Representative 2 mm^3^ areas were removed from the tissue block and homogenized in the presence of Trizol reagent (Life Technologies, Gaithersburg, MD) and total cellular RNA was purified according to the manufacturer\'s standard protocol. RNA was then further purified using miRVANA (Ambion, Austin, TX) according to the manufacturer\'s protocol. After purification, RNA quality was assessed by Agilent Bioanalyzer.

cRNA synthesis and gene expression profiling {#S13}
--------------------------------------------

Human 133 Plus 2.0 microarrays (Affymetrix, Santa Clara, CA) were used, which consist of \>54,000 probe-sets representing approximately 47,400 transcripts. Preparation of cRNA hybridization was performed according to manufacturer\'s protocols. GeneChips were scanned using the Affymetrix 3000 7G GeneChip Scanner with Autoloader and processed by the Affymetrix Gene Chip Command Console version 3.2. Samples were analyzed in two batches, with overlapping specimens included to control for batch effect. Due to lack of overlapping samples, batch effect could not be corrected for the *in silico* comparison between MCC and normal skin. Expression data has been made available in the GEO database (accession number GSE39612).

Statistical analysis {#S14}
--------------------

For DNA microarrays, log2 gene expression values were calculated using a robust multi-array average. Adjusted p-value was calculated using the Benjamini and Hochberg False Discovery Rate concept ([@R5]). For all analyses, a fold change of ≥ 2.0 or ≤ 0.5 with an adjusted p-value of ≤ 0.05 was considered statistically significant. Array quality was evaluated by standard error estimates for each gene standardized across all arrays after fitting a probe level model using the affyPLM package of Bioconductor ([@R10]). One sample was eliminated due to elevated standard errors. Age was described and tested between MCPyV-positive and negative groups using means, standard deviations and corresponding t-tests. Anatomical site was compared between MCPyV groups with Fisher\'s exact test. Further details on statistical analyses are provided in [Supplemental Materials and Methods](#SD1){ref-type="supplementary-material"}.

Characterization of MCPyV status in MCC tumors {#S15}
----------------------------------------------

PCR of isolated genomic tumor DNA was performed to detect the presence of MCPyV DNA in tumor samples. Because tumors that contain MCPyV DNA but lack LTAg expression are reported to be more similar to MCPyV-negative tumors with regard to clinical outcome ([@R55]), we also characterized RNA expression of MCPyV large and small T antigens by RT-PCR. Tumor RNA was used to prepare cDNA according to standard protocols. Briefly, 0.25 µg RNA was utilized for first strand cDNA synthesis with SuperScript™ II Reverse Transcriptase (Invitrogen) as per manufacturer\'s directions. Detection of MCPyV sequence (based on GenBank NC_010277) was conducted by semi-quantitative PCR on tumor cDNA and/or genomic DNA using primers TA1, targeting the exon 1 coding region common to all T antigen transcripts (forward primer: nucleotides (nts) 226-245, reverse primer: nts 357-376), and TA2, targeting the exon 1 coding region specific to small T antigen only (forward primer: nts 354-373, reverse primer: nts 571-590). Results were further confirmed using the previously described primers for capsid viral protein (VP1)([@R19]). Human beta-actin primers were used as a control. As a control for a gene expressed in Merkel cell carcinoma, primers were used for atonal homolog 1 (GenBank NP_005163; forward primer: nts 230-249, reverse primer: nts 444-463). All primers were designed using Primer3 (<http://fokker.wi.mit.edu/primer3/input.htm>). PCR products were separated by agarose gel and visualized by ethidium bromide. Three tumors were excluded due to insufficient tissue or degraded DNA. An additional tumor was excluded due to equivocal results for TAg mRNA expression. Of the remaining 26 tumors, twelve (46%) had both MCPyV DNA and mRNA, and fourteen (54%) lacked both MCPyV DNA and mRNA.

Immunohistochemistry {#S16}
--------------------

A tissue microarray (TMA) of profiled tumors was constructed, with each tumor represented by two 1.0 mm cores. Tumor content of each core was verified by H&E stain. Immunohistochemistry was performed using a DAKO automated stainer as previously described ([@R62]). Antibodies and dilutions are described in [Supplemental Materials and Methods](#SD1){ref-type="supplementary-material"}.

For RB, the percentage of tumor cells labeled was recorded as one of three categories: \< 10% (negative), 10--50% (intermediate) and \>50% (diffuse). All positive cases displayed a nuclear pattern of staining. RB staining was compared between MCPyV groups with Fisher\'s exact test.

For CD20, CD3, CD4, and CD8, peritumoral and tumor-infiltrating lymphocytes were counted across two 1 mm tissue microarray cores for each tumor. Wilcoxon rank test was used to test differences in CD20+, CD3+, CD4+, and CD8+ peritumoral and tumor-infiltrating lymphocytes measures between MCPyV groups.

Supplementary Material {#S17}
======================

###### 

**Supplemental figure S1. Genes with greatest differential expression between Merkel cell and cutaneous squamous cell carcinoma.** All genes shown have adjusted p-value ≤ 0.05. Fold values are in log2. SCC: cutaneous squamous cell carcinoma. MCC: Merkel cell carcinoma. CL: Merkel cell carcinoma cell lines.

**Supplemental figure S2. Gene groups differentially regulated in Merkel cell carcinoma relative to squamous cell carcinoma by parametric gene set enrichment analysis.** (a) Analysis of genes upregulated in Merkel cell carcinoma reveals similarities to tumors including neuroblastoma. (b) Genes downregulated in MCC relative to SCC.

**Supplemental figure S3. Principal component analysis of Merkel cell carcinoma transcriptional profiles relative to normal skin.** Merkel cell carcinomas have a distinct expression profile compared to normal skin. Solid circles indicate normal skin. Open squares indicate Merkel cell carcinoma (MCC). PC1: principal component 1. PC2: principal component 2.

**Supplemental figure S4. RT-PCR detection of Merkel cell polyomavirus T antigen and VP1 expression in Merkel cell carcinoma.** Viral gene expression in cDNA prepared from tumor tissue was analyzed using primers targeting Merkel cell polyomavirus large T antigen and small T antigen (LTAg+STAg, primer pair TA1), small T antigen only (STAg, primer pair TA2), or viral capsid protein 1 (VP1). Atonal homolog 1 (ATOH1) is included as a control gene expressed in Merkel cell carcinoma. Beta-actin is included as a loading control. Patient and case numbers are as shown in [Table 1](#T1){ref-type="table"}.

**Table S1. RNA expression of selected genes in Merkel cell carcinoma relative to squamous cell carcinoma.** ^1^A central value for each probe-set was determined by averaging log-transformed data, and taking the anti-logarithm. A fold difference of ≥ 2.0 with adjusted p-value ≤ 0.05 was considered statistically significant.

**Table S2. Selected functional classes, by gene ontology, for genes with significantly higher RNA expression in Merkel cell carcinoma relative to squamous cell carcinoma.** ^1^MCC: Merkel cell carcinoma. ^2^SCC: squamous cell carcinoma.

**Table S3. RNA expression of selected genes in Merkel cell carcinoma relative to basal cell carcinoma.** ^1^A central value for each probe-set was determined by averaging log-transformed data, and taking the anti-logarithm. A fold difference of ≥ 2.0 with adjusted p-value ≤ 0.05 was considered statistically significant. Fold changes shown represent expression in Merkel cell carcinomas relative to basal cell carcinomas.

**Table S4. RNA expression of selected genes in Merkel cell carcinoma relative to normal skin.** ^1^A central value for each probe-set was determined by averaging log-transformed data, and taking the anti-logarithm. A fold difference of ≥ 2.0 with adjusted p-value ≤ 0.05 was considered statistically significant. Fold changes shown represent expression in Merkel cell carcinomas relative to normal skin.
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![Principal component analysis of Merkel cell carcinoma transcriptional profiles relative to Merkel cell carcinoma cell lines and nonmelanoma skin cancers\
Merkel cell carcinomas have a distinct expression profile compared to squamous cell and basal cell carcinomas. Solid squares indicate primary cutaneous squamous cell carcinomas (SCC). Solid circles indicate basal cell carcinomas (BCC). Solid triangles indicate Merkel cell carcinoma primary tumors (MCC). Open triangles indicate metastatic MCC tumors (Met). Asterisks indicate MCC cell lines. PC1: principal component 1. PC2: principal component 2.](nihms416390f1){#F1}

![Principal component analysis of Merkel cell carcinoma tumors by Merkel cell polyomavirus status\
The majority of Merkel cell polyomavirus (MCPyV)-positive tumors (open circles) display a distinct cluster which partially overlaps with MCPyV-negative tumors (solid squares). MCPyV-negative tumors are more heterogeneous. Negative: MCPyV T antigen (TAg) DNA and RNA negative. Positive: TAg DNA and RNA positive. PC1: principal component 1. PC2: principal component 2.](nihms416390f2){#F2}

![Genes with greatest differential expression in Merkel cell polyomavirus-positive tumors relative to -negative tumors\
All genes shown have adjusted p-value ≤ 0.05. Fold values are in log2.](nihms416390f3){#F3}

![Merkel cell polyomavirus negativity is associated with relatively decreased immune response and loss of Retinoblastoma expression\
Relative to Merkel cell polyomavirus-negative tumors (a-c), Merkel cell polyomavirus-positive tumors (d-f) display a trend toward increased CD3+ peritumoral lymphocytes (a, d, g), low CD4+ T lymphocytes (b, e, g) and significantly increased CD8+ T lymphocytes (c, f, g) by immunohistochemistry. Merkel cell polyomavirus-positive tumors uniformly express RB (h, j), whereas the majority of Merkel cell polyomavirus-negative tumors display loss of RB expression by immunohistochemistry (i, j). Scale bar = 50 microns.](nihms416390f4){#F4}

###### 

Patient and tumor characteristics of profiled cases.

                                                                                                                                                            Primary tumor                                  
  -------- ---- ---------------------------------------------- --- --- ---- ------------------------------------ ------------------------------------- ---- ----------------------------------- ---------- -----------
  1        1    Primary/skin                                   M   3   65   no                                   DOD[2](#TFN2){ref-type="table-fn"}    13   ≥7                                  shoulder   negative
  2        2    Primary/skin                                   F   1   82   no                                   DOC[3](#TFN3){ref-type="table-fn"}    36   ND[7](#TFN7){ref-type="table-fn"}   leg        positve
  3        3    Primary/skin                                   M   2   88   no                                   DOC                                   23   \>6                                 leg        positive
  4        4    Primary/skin                                   M   1   81   no                                   AWED[4](#TFN4){ref-type="table-fn"}   41   3.3                                 forehead   negative
  5        5    Primary/skin                                   M   1   59   yes                                  DOD                                   15   \>2.2                               ear        negative
  6        6    Primary/skin                                   M   1   70   no                                   AWED                                  33   \>4                                 ear        negative
  7        7    Primary/skin                                   F   1   85   no                                   LTFU[5](#TFN5){ref-type="table-fn"}        5.5                                 cheek      positive
  8        8    Primary/skin                                   F   2   68   no                                   AWED                                  37   1.85                                leg        ND
  9        9    Primary/skin                                   F   2   77   no                                   AWED                                  7    ≥9                                  eyelid     positive
  10       10   Primary/skin                                   M   3   80   no                                   AWED                                  18   ≥ 4.1                               arm        positive
  11       11   Primary/skin                                   M   1   59   no                                   AWED                                  13   3.8                                 arm        positive
  12       12   Primary/skin                                   F   1   75   no                                   AWED                                  12   4.8                                 leg        positive
  13       13   Primary/skin                                   M   1   85   no                                   AWED                                  6    9                                   hand       negative
  14       14   Primary/skin                                   F   2   77   no                                   AWED                                  12   ≥9                                  cheek      negative
  15       15   Primary/skin                                   M   2   78   no                                   DOD                                   7    3.1                                 cheek      negative
  16       16   Primary/skin                                   M   1   80   no                                   AWED                                  6    ≥ 2.5                               leg        positive
  17       17   Metastasis/skin                                F   3   78   no                                   DOD                                   14   6                                   leg        ND
  18       18   Metastasis/skin                                M   3   85   no                                   DOD                                   12   ≥5                                  nose       negative
  19       19   Metastasis/skin                                M   3   69   no                                   DOD                                   17   \>6                                 temple     negative
  20       20   Metastasis/skin                                F   3   67   yes^9^                               DOD                                   16   10                                  forearm    positive
  21       21   Metastasis/skin                                F   3   57   no                                   AWED                                  62   ND                                  foot       positive
  22       22   Metastasis/parotid                             F   3   85   no                                   DOD                                   9    18                                  cheek      positive
  23       23   Metastasis/parotid                             F   3   90   no                                   AWED                                  12   9                                   temple     negative
  24       24   Metastasis/LN[8](#TFN8){ref-type="table-fn"}   F   3   79   no                                   AWED                                  20   12                                  arm        positive
  25       25   Primary/skin                                   F   2   85   no                                   DOD                                   27   ND                                  arm        ND
  \(25\)   26   Metastasis/skin                                                                                                                                                                            negative
  26       27   Primary/skin                                   M   2   53   yes                                  AWRD[6](#TFN6){ref-type="table-fn"}   10   19                                  arm        negative
  \(26\)   28   Metastasis/LN                                                                                                                                                                              negative
  27       29   Primary/skin                                   M   1   71   yes[9](#TFN9){ref-type="table-fn"}   DOD                                   25   4                                   neck       equivocal
  \(27\)   30   Metastasis/parotid                                                                                                                                                                         negative

MCPyV status was determined by PCR of tumor genomic DNA and cDNA, as described in the text.

DOD: died of disease.

DOC: died of other causes.

AWED: alive without evidence of disease.

LTFU: lost to followup.

AWRD: alive with residual disease.,

ND: Not determined (due to lack of PCR-quality DNA in the case of MCPyV status).

LN: lymph node.

Patient with history of chronic lymphocytic leukemia.

###### 

Functional gene classes enriched in Merkel cell polyomavirus-negative compared to -positive tumors.

  KEGG pathway[1](#TFN10){ref-type="table-fn"}, probe-set   Gene     Description                                                    Fold[2](#TFN11){ref-type="table-fn"}
  --------------------------------------------------------- -------- -------------------------------------------------------------- --------------------------------------
  *Axon guidance*                                                                                                                   
   229288_at                                                EPHA7    EPH receptor A7                                                4.41
   214607_at                                                PAK3     p21 protein (Cdc42/Rac)-activated kinase 3                     4.72
   231325_at                                                UNC5D    unc-5 homolog D (C. elegans)                                   4.29
   200965_s\_at                                             ABLIM1   actin binding LIM protein 1                                    3.53
   227449_at                                                EPHA4    EPH receptor A4                                                3.27
   230425_at                                                EPHB1    EPH receptor B1                                                4.06
   209589_s\_at                                             EPHB2    EPH receptor B2                                                2.50
   236088_at                                                NTNG1    netrin G1                                                      2.36
   213169_at                                                SEMA5A   semaphorin 5A                                                  2.03
   223610_at                                                SEMA5B   semaphorin 5B                                                  2.16
   32541_at                                                 PPP3CC   protein phosphatase 3, catalytic subunit, gamma isozyme        0.49
   212298_at                                                NRP1     neuropilin 1                                                   0.48
   240425_x\_at                                             ROBO2    roundabout, axon guidance receptor, homolog 2 (Drosophila)     0.43
   227955_s\_at                                             EFNA5    ephrin-A5                                                      0.29
   213603_s\_at                                             RAC2     rho family, small GTP binding protein Rac2                     0.36
   206941_x\_at                                             SEMA3E   semaphorin 3E                                                  0.11
  *Pathways in cancer*                                                                                                              
   208606_s\_at                                             WNT4     wingless-type MMTV integration site family, member 4           3.94
   203638_s\_at                                             FGFR2    fibroblast growth factor receptor 2                            2.75
   210512_s\_at                                             VEGFA    vascular endothelial growth factor A                           2.73
   205463_s\_at                                             PDGFA    platelet-derived growth factor alpha polypeptide               2.25
   230288_at                                                FGF14    fibroblast growth factor 14                                    2.06
   227271_at                                                FGF11    fibroblast growth factor 11                                    2.07
   227314_at                                                ITGA2    integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)   2.25
   221029_s\_at                                             WNT5B    wingless-type MMTV integration site family, member 5B          2.04
   239178_a                                                 FGF9     fibroblast growth factor 9 (glia-activating factor)            0.43
   203132_at                                                RB1      retinoblastoma 1                                               0.41
   223709_s\_at                                             WNT10A   wingless-type MMTV integration site family, member 10A         0.28
  *Notch signaling pathway*                                                                                                         
   224215_s\_at                                             DLL1     delta-like 1 (Drosophila)                                      4.99
   201218_at                                                CTBP2    C-terminal binding protein 2                                   2.71
   203394_s\_at                                             HES1     hairy and enhancer of split 1, (Drosophila)                    2.50
   32137_at                                                 JAG2     jagged 2                                                       2.35
   216268_s\_at                                             JAG1     jagged 1                                                       2.25
  *Neuroactive ligand-receptor interaction*                                                                                         
   209990_s\_at                                             GABBR2   gamma-aminobutyric acid (GABA) B receptor, 2                   7.94
   231192_at                                                LPAR3    lysophosphatidic acid receptor 3                               5.98
   221107_at                                                CHRNA9   cholinergic receptor, nicotinic, alpha 9                       4.41
   231384_at                                                GRIN2A   glutamate receptor, ionotropic, N-methyl D-aspartate 2A        2.69
   209793_at                                                GRIA1    glutamate receptor, ionotropic, AMPA 1                         2.62
   213506_at                                                F2RL1    coagulation factor II (thrombin) receptor-like 1               2.30
   229944\_ at                                              OPRK1    opioid receptor, kappa 1                                       2.14
   229309_at                                                ADRB1    adrenergic, beta-1-, receptor                                  2.0
   230593_at                                                GRIK3    glutamate receptor, ionotropic, kainate 3                      2.03
   206128_at                                                ADRA2C   adrenergic, alpha-2C-, receptor                                0.41
   205279_s\_at                                             GLRB     glycine receptor, beta                                         0.38
   211772_x\_at                                             CHRNA3   cholinergic receptor, nicotinic, alpha 3                       0.36
   229686_at                                                P2RY8    purinergic receptor P2Y, G-protein coupled, 8                  0.39
   213845_at                                                GRIK2    glutamate receptor, ionotropic, kainate 2                      0.38
   207307_at                                                HTR2C    5-hydroxytryptamine (serotonin) receptor 2C                    0.38

KEGG pathways for each gene group are shown in italics. Note that although a functional class/pathway may be upregulated as a whole by KEGG analysis, some individual genes within a class may not display upregulation.

Fold change represents relative array transcript expression in MCPyV-negative Merkel cell carcinoma (MCC) relative to MCPyV-positive MCC. A central value for each probe-set was determined by averaging log-transformed data, and taking the anti-logarithm.
